# Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer

> **NCT05003752** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **German Oncology Center, Cyprus** · enrollment: 40 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Radiation Toxicity

## Interventions

- **RADIATION:** External beam radiation therapy, High-dose-rate brachytherapy
- **DRUG:** Goserelin 10.8 mg

## Key facts

- **NCT ID:** NCT05003752
- **Lead sponsor:** German Oncology Center, Cyprus
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2026-08-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05003752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05003752, "Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05003752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*